Logo image of LSTA

LISATA THERAPEUTICS INC (LSTA) Stock Fundamental Analysis

NASDAQ:LSTA - Nasdaq - US1280583022 - Common Stock - Currency: USD

2.5488  -0.01 (-0.57%)

Fundamental Rating

2

Overall LSTA gets a fundamental rating of 2 out of 10. We evaluated LSTA against 571 industry peers in the Biotechnology industry. While LSTA seems to be doing ok healthwise, there are quite some concerns on its profitability. LSTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LSTA had negative earnings in the past year.
In the past year LSTA has reported a negative cash flow from operations.
In the past 5 years LSTA always reported negative net income.
LSTA had a negative operating cash flow in each of the past 5 years.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M

1.2 Ratios

LSTA has a Return On Assets (-54.29%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -61.56%, LSTA is in line with its industry, outperforming 59.68% of the companies in the same industry.
Industry RankSector Rank
ROA -54.29%
ROE -61.56%
ROIC N/A
ROA(3y)-46.9%
ROA(5y)-46.91%
ROE(3y)-51.49%
ROE(5y)-54.52%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LSTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for LSTA has been increased compared to 1 year ago.
Compared to 5 years ago, LSTA has more shares outstanding
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

LSTA has an Altman-Z score of -18.06. This is a bad value and indicates that LSTA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LSTA (-18.06) is worse than 85.44% of its industry peers.
LSTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.06
ROIC/WACCN/A
WACCN/A
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

LSTA has a Current Ratio of 8.03. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
LSTA has a better Current ratio (8.03) than 72.47% of its industry peers.
LSTA has a Quick Ratio of 8.03. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LSTA (8.03) is better than 72.65% of its industry peers.
Industry RankSector Rank
Current Ratio 8.03
Quick Ratio 8.03
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

LSTA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.34%.
EPS 1Y (TTM)6.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.47% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.16%
EPS Next 2Y4.56%
EPS Next 3Y15.66%
EPS Next 5Y8.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

LSTA's earnings are expected to grow with 15.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.56%
EPS Next 3Y15.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LSTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LISATA THERAPEUTICS INC

NASDAQ:LSTA (2/21/2025, 8:00:00 PM)

2.5488

-0.01 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners9.39%
Inst Owner Change-100%
Ins Owners7.17%
Ins Owner Change26.16%
Market Cap21.38M
Analysts82.22
Price Target14.62 (473.6%)
Short Float %0.31%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.09%
Min EPS beat(2)21.31%
Max EPS beat(2)22.88%
EPS beat(4)4
Avg EPS beat(4)20.9%
Min EPS beat(4)12.1%
Max EPS beat(4)27.3%
EPS beat(8)8
Avg EPS beat(8)22.26%
EPS beat(12)10
Avg EPS beat(12)-44.77%
EPS beat(16)12
Avg EPS beat(16)-38.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.38%
PT rev (3m)2.38%
EPS NQ rev (1m)10.06%
EPS NQ rev (3m)10.06%
EPS NY rev (1m)2.39%
EPS NY rev (3m)8.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)-2.51
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS4.02
TBVpS3.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.29%
ROE -61.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.9%
ROA(5y)-46.91%
ROE(3y)-51.49%
ROE(5y)-54.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.03
Quick Ratio 8.03
Altman-Z -18.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)171.43%
Cap/Depr(5y)109.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.23%
EPS Next Y-5.16%
EPS Next 2Y4.56%
EPS Next 3Y15.66%
EPS Next 5Y8.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.95%
EBIT Next 3Y-3.19%
EBIT Next 5Y-3.25%
FCF growth 1Y3.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.12%
OCF growth 3YN/A
OCF growth 5YN/A